Compare Ascendis Pharma A/S (ASND) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Unity Software Inc — how do they compare? Ascendis Pharma A/S trades at $263.88 (market cap $17.74B), while Unity Software Inc trades at $30.87 (market cap $13.48B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| ASND | U | |
|---|---|---|
Market Cap | $17.74B | $13.48B |
Sector | Health | Technology |
52-Week High | $277.18 | $49.47 |
52-Week Low | $163.32 | $17.13 |
Enterprise Value | $18.11B | $13.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Unity Software (U) trades at $30.89, up 0.52% today, with a bullish technical signal and strong analyst consensus. The stock shows improving revenue trends ($1.85B in 2025) and narrowing losses, though profitability remains negative. Recent news highlights momentum in AI advertising and cost restructuring, with Q2 2026 earnings expected on August 5, 2026.
Outlook: Growth potential exists through AI integration and margin expansion, but persistent net losses and high valuation multiples pose risks. Analyst price target of $36.50 suggests 18% upside, supported by bullish sentiment, yet investors must weigh execution risks against transformative opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
